EYWA Biotech
This biotechnology company develops and manufactures clinical-grade Active Pharmaceutical Ingredients (APIs) of psilocybin, DMT, and 5-MeO-DMT for research and commercial applications. They utilize cutting-edge biosynthetic processes to create scalable, cost-effective, and environmentally friendly psychedelic compounds. EYWA partners with pharmaceutical companies and research institutions to supply high-purity materials supporting next-generation mental health treatments.
- Biotechnology
Funding
Raised to date
$100KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
- afford.capital (opens in a new tab)investor website
Founders
Product
Problem
Current mental health treatments often focus on symptom mitigation rather than addressing the root causes of conditions like treatment-resistant depression, general anxiety, and PTSD. Traditional methods of producing psychedelic compounds for research and therapeutic applications are often inefficient, environmentally unsustainable, and lack scalability.
Solution
EYWA Biotech utilizes synthetic biology and gene engineering to produce clinical-grade, GMP-certified psychedelic APIs, including psilocybin, DMT, and 5-MeO-DMT. Their biomanufacturing process leverages scalable microorganisms to produce these compounds in fewer steps, reducing production time, environmental impact, and costs. This approach ensures a reliable, high-quality, and sustainable supply chain of psychedelic compounds for research, clinical trials, and commercial applications in legal jurisdictions. EYWA's innovative formulations aim to maximize therapeutic benefits and expand treatment horizons, contributing to the advancement of personalized treatments for mental health disorders.
Target Audience
EYWA Biotech's primary customers include pharmaceutical companies, clinics, and research institutions focused on developing and providing psychedelic therapies for mental health disorders.
Features
- Production of GMP-certified psychedelic APIs (psilocybin, DMT, 5-MeO-DMT, and novel molecules)
- Utilizes synthetic biology and gene engineering for efficient production
- Scalable bioreactor-based biosynthesis ensures consistent and efficient production
- Reduced environmental footprint compared to traditional chemical synthesis
- High-purity compounds manufactured under GMP standards
- Decentralized production model to address cross-border logistics challenges
- Development of novel full-spectrum formulations